Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
5887 | 1563 | 38.1 | 73% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
489 | 3 | CISPLATIN//STABILITY CONSTANTS//JOURNAL OF INORGANIC BIOCHEMISTRY | 23107 |
1065 | 2 | CISPLATIN//NEPHROTOXICITY//PLATINUMII COMPLEXES | 9996 |
5887 | 1 | SATRAPLATIN//JM216//PLATINUM BASED DRUG | 1563 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | SATRAPLATIN | authKW | 365132 | 2% | 69% | 27 |
2 | JM216 | authKW | 363639 | 1% | 85% | 22 |
3 | PLATINUM BASED DRUG | address | 312555 | 1% | 100% | 16 |
4 | PLATINUMII COMPLEXES | authKW | 282048 | 5% | 20% | 71 |
5 | LOBAPLATIN | authKW | 255517 | 1% | 59% | 22 |
6 | LIPOSOMAL CISPLATIN | authKW | 235810 | 1% | 93% | 13 |
7 | LIPOPLATIN | authKW | 192329 | 1% | 62% | 16 |
8 | JIANGSU PROV HITECH BIOMED | address | 167457 | 2% | 26% | 33 |
9 | PLATINUM COMPLEXES | authKW | 162055 | 6% | 9% | 94 |
10 | MOE MED CHEM MOL DIAGNOST | address | 143843 | 1% | 82% | 9 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Chemistry, Inorganic & Nuclear | 9917 | 29% | 0% | 447 |
2 | Chemistry, Medicinal | 2638 | 13% | 0% | 199 |
3 | Oncology | 2581 | 22% | 0% | 350 |
4 | Pharmacology & Pharmacy | 1258 | 19% | 0% | 290 |
5 | Chemistry, Multidisciplinary | 823 | 17% | 0% | 270 |
6 | Crystallography | 297 | 4% | 0% | 68 |
7 | Materials Science, Biomaterials | 257 | 2% | 0% | 37 |
8 | Biochemistry & Molecular Biology | 247 | 15% | 0% | 232 |
9 | Chemistry, Organic | 28 | 4% | 0% | 58 |
10 | Nanoscience & Nanotechnology | 17 | 2% | 0% | 34 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PLATINUM BASED DRUG | 312555 | 1% | 100% | 16 |
2 | JIANGSU PROV HITECH BIOMED | 167457 | 2% | 26% | 33 |
3 | MOE MED CHEM MOL DIAGNOST | 143843 | 1% | 82% | 9 |
4 | PLATFORM TRANSLAT CANC THER Y | 65992 | 1% | 24% | 14 |
5 | STATE ADV TECHNOL PGMS | 58604 | 0% | 100% | 3 |
6 | STATE PLATINUM GRP MET | 48832 | 0% | 50% | 5 |
7 | UNIT GIGA SIGNAL TRANSDUCT | 39069 | 0% | 100% | 2 |
8 | CELL VIRUS BANK | 35160 | 0% | 60% | 3 |
9 | NANOTHER EUT | 35154 | 0% | 30% | 6 |
10 | NANOSCALE ORG DYNAM GRP | 33021 | 1% | 11% | 15 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF INORGANIC BIOCHEMISTRY | 32626 | 6% | 2% | 97 |
2 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 9512 | 4% | 1% | 60 |
3 | ANTI-CANCER DRUGS | 4650 | 2% | 1% | 28 |
4 | INORGANICA CHIMICA ACTA | 3809 | 4% | 0% | 58 |
5 | DALTON TRANSACTIONS | 3785 | 4% | 0% | 60 |
6 | JOURNAL OF COORDINATION CHEMISTRY | 3478 | 2% | 1% | 33 |
7 | METALLOMICS | 3208 | 1% | 1% | 13 |
8 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 3133 | 2% | 0% | 39 |
9 | JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY | 1878 | 1% | 1% | 14 |
10 | INORGANICA CHIMICA ACTA-BIOINORGANIC CHEMISTRY | 1768 | 1% | 1% | 9 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SATRAPLATIN | 365132 | 2% | 69% | 27 | Search SATRAPLATIN | Search SATRAPLATIN |
2 | JM216 | 363639 | 1% | 85% | 22 | Search JM216 | Search JM216 |
3 | PLATINUMII COMPLEXES | 282048 | 5% | 20% | 71 | Search PLATINUMII+COMPLEXES | Search PLATINUMII+COMPLEXES |
4 | LOBAPLATIN | 255517 | 1% | 59% | 22 | Search LOBAPLATIN | Search LOBAPLATIN |
5 | LIPOSOMAL CISPLATIN | 235810 | 1% | 93% | 13 | Search LIPOSOMAL+CISPLATIN | Search LIPOSOMAL+CISPLATIN |
6 | LIPOPLATIN | 192329 | 1% | 62% | 16 | Search LIPOPLATIN | Search LIPOPLATIN |
7 | PLATINUM COMPLEXES | 162055 | 6% | 9% | 94 | Search PLATINUM+COMPLEXES | Search PLATINUM+COMPLEXES |
8 | PLATINUMIV COMPLEXES | 131286 | 1% | 31% | 22 | Search PLATINUMIV+COMPLEXES | Search PLATINUMIV+COMPLEXES |
9 | PTIV COMPLEXES | 130225 | 1% | 67% | 10 | Search PTIV+COMPLEXES | Search PTIV+COMPLEXES |
10 | ORMAPLATIN | 119648 | 0% | 88% | 7 | Search ORMAPLATIN | Search ORMAPLATIN |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | JOHNSTONE, TC , SUNTHARALINGAM, K , LIPPARD, SJ , (2016) THE NEXT GENERATION OF PLATINUM DRUGS: TARGETED PT(II) AGENTS, NANOPARTICLE DELIVERY, AND PT(IV) PRODRUGS.CHEMICAL REVIEWS. VOL. 116. ISSUE 5. P. 3436 -3486 | 161 | 33% | 56 |
2 | OUN, R , WHEATE, NJ , WALKER, S , CRAIG, GE , (2010) THE STATUS OF PLATINUM ANTICANCER DRUGS IN THE CLINIC AND IN CLINICAL TRIALS.DALTON TRANSACTIONS. VOL. 39. ISSUE 35. P. 8113 -8127 | 89 | 49% | 474 |
3 | WILSON, JJ , LIPPARD, SJ , (2014) SYNTHETIC METHODS FOR THE PREPARATION OF PLATINUM ANTICANCER COMPLEXES.CHEMICAL REVIEWS. VOL. 114. ISSUE 8. P. 4470 -4495 | 120 | 38% | 100 |
4 | HAN, XP , SUN, J , WANG, YJ , HE, ZG , (2015) RECENT ADVANCES IN PLATINUM (IV) COMPLEX-BASED DELIVERY SYSTEMS TO IMPROVE PLATINUM (II) ANTICANCER THERAPY.MEDICINAL RESEARCH REVIEWS. VOL. 35. ISSUE 6. P. 1268 -1299 | 81 | 53% | 11 |
5 | GIBSON, D , (2016) PLATINUM(IV) ANTICANCER PRODRUGS - HYPOTHESES AND FACTS.DALTON TRANSACTIONS. VOL. 45. ISSUE 33. P. 12983 -12991 | 45 | 71% | 7 |
6 | FANELLI, M , FORMICA, M , FUSI, V , GIORGI, L , MICHELONI, M , PAOLI, P , (2016) NEW TRENDS IN PLATINUM AND PALLADIUM COMPLEXES AS ANTINEOPLASTIC AGENTS.COORDINATION CHEMISTRY REVIEWS. VOL. 310. ISSUE . P. 41 -79 | 71 | 31% | 12 |
7 | RAVERA, M , GABANO, E , PELOSI, G , FREGONESE, F , TINELLO, S , OSELLA, D , (2014) A NEW ENTRY TO ASYMMETRIC PLATINUM(IV) COMPLEXES VIA OXIDATIVE CHLORINATION.INORGANIC CHEMISTRY. VOL. 53. ISSUE 17. P. 9326 -9335 | 41 | 82% | 11 |
8 | DONG, JR , REN, YL , HUO, SY , SHEN, SG , XU, JZ , TIAN, HW , SHI, TS , (2016) REDUCTION OF ORMAPLATIN AND CIS-DIAMMINETETRACHLOROPLATINUM(IV) BY ASCORBIC ACID AND DOMINANT THIOLS IN HUMAN PLASMA: KINETIC AND MECHANISTIC ANALYSES.DALTON TRANSACTIONS. VOL. 45. ISSUE 28. P. 11326 -11337 | 45 | 73% | 1 |
9 | HALL, MD , DOLMAN, RC , HAMBLEY, TW , (2004) PLATINUM(IV) ANTICANCER COMPLEXES.METAL IONS IN BIOLGICAL SYSTEMS, VOL 42: METAL COMPLEXES IN TUMOR DIAGNOSIS AND AS ANTICANCER AGENTS. VOL. 42. ISSUE . P. 297 -322 | 51 | 82% | 50 |
10 | WONG, E , GIANDOMENICO, CM , (1999) CURRENT STATUS OF PLATINUM-BASED ANTITUMOR DRUGS.CHEMICAL REVIEWS. VOL. 99. ISSUE 9. P. 2451 -2466 | 60 | 38% | 1303 |
Classes with closest relation at Level 1 |